Toxicity refers to the ability of an active substance, its metabolites or a formulation to elicit adverse biological effects at a certain exposure. In drug development, it is not a single study result, but the systematic description of adverse effects by dose, duration, route of exposure and affected organs. Toxicological data establish whether and under what conditions administration to humans can be justifiably investigated further.<\/p>\n
General toxicity is investigated after single or repeated administration. Acute toxicity describes findings after a single or very short exposure. Subchronic studies record effects after repeated administration over a limited period; chronic studies consider potential consequences of prolonged, repeated exposure. Crucial factors are not only clinical signs, but also clinical chemistry, hematology, body weight, organ findings and histopathological changes. Trial duration and investigated species are adapted to the planned clinical use and stage of development.<\/p>\n
In addition, specific hazards are assessed. Genotoxicity captures the potential to damage genetic material. Reproductive toxicity investigates potential effects on fertility as well as embryo-fetal and postnatal development. Carcinogenicity concerns the potential for long-term tumor induction and is not required for every active substance in the same phase of development. Depending on pharmacological properties, local tolerance, phototoxicity, immunotoxicity or toxicity in juvenile animals may additionally be relevant.<\/p>\n
Toxicity cannot be meaningfully interpreted without reference to dose and systemic exposure. Toxicokinetic accompaniment links administered dose, concentration time course and observed findings. The NOAEL is the highest tested dose at which no adverse effects were observed. It is an important, but not in isolation sufficient, basis for selecting a safe starting dose and for exposure margins. If suitable effects are missing or the dose-response relationship is unclear, other scientifically justified points of departure may be required.<\/p>\n
The maximum tolerated dose, MTD for short, describes in the respective investigation context a dose with still acceptable burden before unacceptable toxicity occurs. It is not to be equated with dose-limiting toxicity: dose-limiting toxicity is a specifically observed event or finding pattern at a clinical dose level; the MTD is the dose level derived from this, relevant for a regimen. A high dose alone is not a quality feature if it does not provide data meaningful for clinical exposure.<\/p>\n
Toxicity is a safety endpoint or a property and finding complex of a substance under defined conditions. Nonclinical development, on the other hand, is a phase of development prior to broad clinical testing. Besides toxicology, it also includes pharmacology, pharmacokinetics, drug development, suitable disease models and the compilation of documents for first-in-human use. Toxicity studies are therefore an essential building block of nonclinical development, but not its synonym.<\/p>\n
Safety pharmacology must also be distinguished. It specifically tests adverse functional effects on vital physiological systems, particularly cardiovascular, respiratory and central nervous systems. Toxicological studies can incorporate such indications, but do not replace risk-based safety pharmacology according to ICH S7A and ICH S7B. The overall view of findings, exposure and reversibility determines the validity for the clinical procedure.<\/p>\n
For clinical trials, toxicological data help determine risk management prior to first administration and during subsequent dose escalations. They influence starting dose, escalation steps, exclusion criteria, safety laboratory, assessment intervals and stopping rules. Authorities and ethics committees assess in particular whether nonclinical data cover the planned exposure, duration and target population. For oncology drugs, ICH S9 considers that disease severity and target population co-determine the nonclinical strategy.<\/p>\n
Full-service CROs such as Mediconomics support the transfer of toxicological findings into the clinical protocol, investigator’s brochure and safety monitoring plan. This includes aligning inclusion and exclusion criteria, planning laboratory and vital sign checks, documenting stopping rules as well as coordinated preparation for regulatory affairs, medical writing, pharmacovigilance and site management.<\/p>\n
Is toxicity to be equated with an adverse drug reaction?<\/strong><\/p>\n No. Toxicity describes the harmful potential and observed findings in toxicological or clinical contexts. An adverse drug reaction is a harmful reaction identified in humans for which a causal relationship with the medicinal product is assessed as at least possible or probable.<\/p>\n What is the NOAEL used for?<\/strong><\/p>\n The NOAEL is a reference point for extrapolating animal data to clinical planning. It is evaluated together with species relevance, exposure, pharmacological effect, safety margins and uncertainties. It does not represent an automatically transferable dose for humans.<\/p>\n Must every medicinal product be tested for carcinogenicity?<\/strong><\/p>\n No. The need depends, among other things, on the duration and type of intended use, target population and available findings. ICH M3(R2) requires an assessment of carcinogenic potential particularly in case of special cause for concern or long-term use.<\/p>\n Toxicity refers to the ability of an active substance, its metabolites or a formulation to elicit adverse biological effects at a certain exposure. In drug development, it is not a single study result, but the systematic description of adverse effects by dose, duration, route of exposure and affected organs. Toxicological data establish whether and under […]<\/p>\n","protected":false},"author":10,"featured_media":0,"parent":0,"template":"","meta":{"_acf_changed":false,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"glossary-cat":[],"class_list":["post-6710","glossary","type-glossary","status-publish","hentry"],"acf":[],"related_terms":"","external_url":"","internal_reference_id":"","_links":{"self":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6710","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary"}],"about":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/types\/glossary"}],"author":[{"embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/users\/10"}],"version-history":[{"count":1,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6710\/revisions"}],"predecessor-version":[{"id":7434,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary\/6710\/revisions\/7434"}],"wp:attachment":[{"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/media?parent=6710"}],"wp:term":[{"taxonomy":"glossary-cat","embeddable":true,"href":"https:\/\/mediconomics.com\/en\/wp-json\/wp\/v2\/glossary-cat?post=6710"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Regulatory references<\/h2>\n
\n